Elcubragistat
Pharmaceutical compound
From Wikipedia, the free encyclopedia
Elcubragistat (INN; developmental code names ABX-1431, Lu-AG06466) is a monoacylglycerol lipase (MAGL) inhibitor which is or was under development for a variety of indications but has not completed development or been marketed as of 2025.[1][2][3][4] It is taken orally.[1]
- None
| |
| Clinical data | |
|---|---|
| Other names | ABX-1431; ABX1431; Lu-AG06466 |
| Routes of administration | Oral[1] |
| Drug class | Monoacylglycerol lipase (MAGL) inhibitor |
| ATC code |
|
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| IUPHAR/BPS | |
| DrugBank | |
| ChemSpider | |
| UNII | |
| ChEMBL | |
| Chemical and physical data | |
| Formula | C20H22F9N3O2 |
| Molar mass | 507.401 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
Pharmacology
The drug acts as a highly potent and selective MAGL inhibitor and hence increases brain levels of the endocannabinoid 2-arachidonoylglycerol (2-AG) without affecting levels of anandamide.[3][4][5] It produces analgesic and other effects in animals.[3][4]
Development
Elcubragistat is or was under development by Abide Therapeutics, Lundbeck, and the University of Oxford.[1][2][3] As of December 2024, no recent development for fibromyalgia, muscle spasticity, neurological disorders, neuropathic pain, non-ulcer dyspepsia, pain, partial epilepsies, post-traumatic stress disorder (PTSD), and an unspecified indication has been reported, whereas development for Tourette's syndrome has been discontinued.[1][2][3] The highest developmental stage that the drug has reached is phase 2 clinical trials.[1][2]